Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

We are a biopharmaceutical company on a mission to develop treatments for serious diseases.

Press Releases

Jul 31, 2023

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 01, 2023

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023

Cyclerion Announces Reverse Stock Split

May 11, 2023

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

view all

Stock Quote

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top